论文部分内容阅读
With the rapid development of China’s economy,China’s pharmaceutical industry market has gradually matured,and more and more capital has poured into the pharmaceutical market,leading to the gradual expansion of competition in the pharmaceutical industry market.At the same time,under the circumstance that the government gradually changes the policy of the pharmaceutical industry in China,the pressure faced by the pharmaceutical enterprises in China can not be ignored.Therefore,under the premise of the gradual unification of commodity quality,pharmaceutical enterprises must have the spirit of continuous innovation and a stricter management system.Only when an enterprise keeps pace with The Times can it mitigate the financial risks it may encounter.At the same time,how to effectively identify their own financial risk and control it is very necessary.According to the current research literature,there are more theoretical studies on financial risks by domestic and foreign researchers,but few studies on specific financial risks of enterprises combined with industry-related characteristics.In this thesis,TJ Company,a representative company in the pharmaceutical industry,is selected to do research.Firstly,the four basic capabilities of TJ Company are evaluated by using the efficiency coefficient method evaluation model combined with the characteristics of related financial risks in the pharmaceutical industry.After that,the specific financial risks in financing,investment,operation and growth capacity of the enterprise are obtained.In combination with the practical situation of the pharmaceutical industry and specific financial situation to build TJ company targeted financial risk early warning system,combining actual financial strength to make reasonable and effective control measures,so as to strengthen enterprise financial risk resistance and make the enterprise can more benign development.Finally,I hope this paper can provide some reference value for the research on financial risk control and early warning of pharmaceutical enterprises in China.